Skip to content

Ibogaine: all studies

Page 19 of 62: studies 181 to 190 of 613, newest first. Back to the ibogaine overview

Research

Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.

Journal of Psychoactive Drugs 2017 Annamarie Heink, Steve Katsikas, Tiffany Lange-Altman 35 citations

Psychedelic drugs have historically been used for ritualistic purposes and to help individuals gain insight. Ibogaine, a naturally occurring psychoactive substance, has been reported to have anti-addictive properties that aid in the treatment of substance use disorders. An online survey obtained retrospective data from individuals who used ibogaine in the past. Individuals who used ibogaine...

Quantification of Anti-Addictive Alkaloids Ibogaine and Voacangine in In Vivo- and In Vitro-Grown Plants of Two Mexican Tabernaemontana Species.

Chemistry & Biodiversity December 1, 2016 Felix Krengel, Josefina Herrera Santoyo, Teresa de Jesús Olivera Flores et al. 19 citations

Tabernaemontana alba and Tabernaemontana arborea are Apocynaceae species used in Mexican traditional medicine for which little phytochemical information exists. In this study, preliminary gas chromatography/mass spectrometry analyses of different organs obtained from wild plants of both species identified a total of 10 monoterpenoid indole alkaloids (MIAs) and one simple indole alkaloid, nine...

DOI: 10.1002/cbdv.201600146 (opens in new tab) Full text (opens in new tab) Ibogaine Tabernaemontana alba Tabernaemontana arborea Monoterpenoid indole alkaloid +8

Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.

Clinical Pharmacology in Drug Development November 1, 2016 Paul Glue, Gavin Cape, Donna Tunnicliff et al. 66 citations

Ibogaine is a psychoactive substance that may reduce opioid withdrawal symptoms. This was the first clinical trial of noribogaine, ibogaine's active metabolite, in patients established on methadone opioid substitution therapy (OST). In this randomized, double-blind, placebo-controlled single ascending-dose study, we evaluated the safety, tolerability, and pharmacokinetics of noribogaine in 27...

Death related to consumption of Rauvolfia sp. powder mislabeled as Tabernanthe iboga.

Forensic Science International September 1, 2016 Thomas Gicquel, Chloé Hugbart, Françoise Le Devehat et al. 20 citations

Powdered roots of iboga (Tabernanthe iboga) contain ibogaine, an alkaloid that has been used to treat addictions. We report the case of a 30-year-old woman who died after ingesting a powder labeled as Tabernanthe iboga she had bought online. Analysis of the powder revealed the absence of ibogaine but the presence of toxic alkaloids (ajmaline, yohimbine and reserpine) found in Rauvolfia sp....

Ibogaine for treating drug dependence. What is a safe dose?

Drug and Alcohol Dependence September 1, 2016 Leo J. Schep, Robin J Slaughter, S Galea et al. 30 citations

The indole alkaloid ibogaine, present in the root bark of the West African rain forest shrub Tabernanthe iboga, has been adopted in the West as a treatment for drug dependence. Treatment of patients requires large doses of the alkaloid to cause hallucinations, an alleged integral part of the patient's treatment regime. However, case reports and case series continue to describe evidences of...

DOI: 10.1016/j.drugalcdep.2016.07.005 (opens in new tab) Full text (opens in new tab) Drug dependence Qt prolongation Ibogaine treatment ibogaine Current ibogaine doses +6

Effects of low dose ibogaine on subjective mood state and psychological performance.

Journal of Ethnopharmacology August 2, 2016 Bridget Forsyth, Liana Machado, Tim Jowett et al. 35 citations

Root bark from Tabernanthe iboga has been used traditionally in West Africa as a psychoactive substance in religious rituals. In smaller doses it is reported anecdotally to have stimulant properties. To evaluate the influence of a single 20mg ibogaine dose on psychological variables reflecting subjective mood state and a range of cognitive functions. 21 healthy male volunteers received single...

DOI: 10.1016/j.jep.2016.05.022 (opens in new tab) Full text (opens in new tab) Noribogaine Ibogaine study: ibogaine Low-dose ibogaine Single 20mg dose +11

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of Psychopharmacology July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 (opens in new tab) Full text (opens in new tab) Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Ibogaine and addiction in the animal model, a systematic review and meta-analysis.

Translational Psychiatry May 31, 2016 Maarten Belgers, M Leenaars, Judith R. Homberg et al. 64 citations

Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in patients with substance use disorders (SUDs). Although human clinical trials on the safety and efficacy of ibogaine are lacking, animal studies do support the efficacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal findings,...

DOI: 10.1038/tp.2016.71 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction treatment Drug self-administration reduction Curbing addictive behaviors +11